BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 15617840)

  • 1. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
    Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
    Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas.
    Wong DJ; Barrett MT; Stöger R; Emond MJ; Reid BJ
    Cancer Res; 1997 Jul; 57(13):2619-22. PubMed ID: 9205067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
    Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
    Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.
    Wong DJ; Paulson TG; Prevo LJ; Galipeau PC; Longton G; Blount PL; Reid BJ
    Cancer Res; 2001 Nov; 61(22):8284-9. PubMed ID: 11719461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
    Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.
    Michael D; Beer DG; Wilke CW; Miller DE; Glover TW
    Oncogene; 1997 Oct; 15(14):1653-9. PubMed ID: 9349498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Park JM; Salonga D; Groshen S; Tsao-Wei DD; DeMeester TR; Hölscher AH; Danenberg PV
    J Surg Res; 2001 Aug; 99(2):301-6. PubMed ID: 11469901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
    Barrett MT; Sanchez CA; Galipeau PC; Neshat K; Emond M; Reid BJ
    Oncogene; 1996 Nov; 13(9):1867-73. PubMed ID: 8934532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach.
    Hayashi K; Metzger R; Salonga D; Danenberg K; Leichman LP; Fink U; Sendler A; Kelsen D; Schwartz GK; Groshen S; Lenz HJ; Danenberg PV
    Oncogene; 1997 Sep; 15(12):1481-8. PubMed ID: 9333024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
    von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
    Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
    Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
    Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.